Clinical Updates

Thirty percent of rheumatoid arthritis patients who failed to respond adequately to anti-TNF therapy achieved remission from their disease when… »   

Health care plans that restrict members’ access to certain arthritis medications due to cost concerns may actually wind up spending… »   

Paris, France, Friday 13 June 2008: New data presented today at EULAR 2008, the Annual Congress of the European League… »   

An experimental treatment for rheumatoid arthritis being developed by Johnson & Johnson and Schering-Plough Corp appeared to be effective… »   

A nearly 7-year study of the effect of intensive blood sugar control with rosiglitazone (Avandia, GlaxoSmithKline) on the progression… »   

Roche Holding AG’s MabThera was more effective in treating rheumatoid arthritis (RA) patients than other drugs with a more traditional… »   

An experimental injectable type 2 diabetes drug being developed by Sanofi-Aventis SA was well tolerated and significantly improved blood sugar… »   

Sanofi-Aventis SA’s drug Acomplia can significantly improve blood sugar control in patients with type 2 diabetes who are not adequately… »   

The Bush administration is asking Congress for an increase of $275 million above its current budget request to enhance… »   

ohnson & Johnson has added a strong “black box” warning about the risk of dying from cancer to the prescribing… »   

The chief executive of Allergan Inc said Wednesday its experimental drug to promote eyelash growth could be a big seller… »   

A drug candidate critical to Takeda Pharmaceutical Co Ltd’s mainstay diabetes franchise is expected to show sufficient promise to gain… »   

Few nursing home patients at high risk of bone fractures are given medications to strengthen their bones, a new… »   

A Chinese court has jailed a man for life for supplying a drug maker a fake ingredient that led to… »   

When they work, new melanoma treatments that enlist the help of the immune system to attack tumors can have a… »